|

Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery

RECRUITINGPhase 2Sponsored by Brigham and Women's Hospital
Actively Recruiting
PhasePhase 2
SponsorBrigham and Women's Hospital
Started2026-06-10
Est. completion2028-10-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site

Summary

The investigators will perform a phase 2a, randomized, double-blind, placebo-controlled clinical trial in adult patients undergoing elective coronary artery bypass grafting (CABG) surgery to investigate the effects of oral nicotinamide mononucleotide (NMN) administration on myocardial NAD+ concentrations and on postoperative markers of myocardial and kidney injury.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Age ≥18 years
2. Scheduled to undergo elective isolated CABG surgery with cardiopulmonary bypass (CPB)
3. At increased risk of postoperative complications based on ≥1 of the following:

   1. Age ≥65 years
   2. eGFR \<45 ml/min/1.73m2
   3. Documented history of congestive heart failure or left ventricular ejection fraction (LVEF) ≤40% within 6 months before surgery
   4. Diabetes mellitus and urine albumin-to-creatinine ratio \>30 mg/g creatinine
   5. Peripheral arterial disease
   6. Anemia, defined as hemoglobin \<10 g/dl
   7. Prior cardiac surgery

Exclusion Criteria:

1. Any of the following laboratory abnormalities at the time of screening:

   1. ALT \>3-fold the upper limit of normal
   2. eGFR \<30 ml/min/1.73m2 or ESKD on dialysis
   3. Hemoglobin \<8 g/dl
2. History of gastric bypass or malabsorption
3. Active alcohol or illicit substance use in the prior 6 months
4. Participation in an investigational trial to evaluate pharmaceuticals or biologics within the past 3 months or 5 half-lives, whichever is shorter
5. Pregnant or breast-feeding
6. Unwillingness to use contraception while taking study drug and for 8 weeks after the last dose for women of reproductive age or non-sterilized male participants who are sexually active with a female partner of childbearing potential
7. Current use of niacin \>100 mg/day or NMN, nicotinamide, or nicotinamide riboside at any dose
8. Conflict with other research studies
9. Any condition which, in the judgement of the investigator, might increase the risk to the participant

Conditions2

Coronary Artery Bypass GraftHeart Disease

Interventions1

Locations1 site

Brigham and Women's Hospital
David E Leaf, MD617-732-5951deleaf@bwh.harvard.edu

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.